A Phase II Study of the Combination of Metronomic Vinorelbine and Bevacizumab as 2nd Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)
Intravenous (IV) vinorelbine is a standard chemotherapy option for the treatment of
metastatic NSCLC, either alone or in combination with other agents such as CDDP or
Carboplatin with overall response rates (ORR) of 15-35% as 1st line treatment and less than
10% as salvage treatment. For the past few years vinorelbine is available for per os (po)
administration with acceptable and reliable pharmacokinetic profiles and with a
bioavailability of approximately 40% of the IV dose. In randomized phase II studies IV and
po vinorelbine have shown comparable response and overall survival rates. The low dose
metronomic chemotherapy that is administered in short intervals has been shown in vitro an
in vivo to have antiangiogenic effects. Bevacizumab is a well known anti-angiogenic agent.
Recently, a phase III study of 1st line treatment in patients with advanced or metastatic
NSCLC showed that the addition of bevacizumab to a platinum-based regimen provided a
survival benefit. This study will evaluate the combination of metronomic vinorelbine and
bevavizumab as 2nd line treatment of NSCLC.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate
Objective responses confirmed by CT or MRI (on 3rd and 6th cycle)
No
Sofia Agelaki, MD
Principal Investigator
University Hospital of Crete, Dep of Medical Oncology
Greece: National Organization of Medicines
CT/08.18
NCT00755170
November 2008
March 2013
Name | Location |
---|